Earnings season is winding down, with most companies already having reported their quarterly results. But there are still some companies left to report, and Sequenom, Inc. (NASDAQ:SQNM) is about to release its quarterly earnings report. The key to making smart investment decisions with stocks releasing their quarterly reports is to anticipate how they’ll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you’ll be less likely to make an uninformed kneejerk reaction to news that turns out to be exactly the wrong move.
Genetic testing is a big potential growth area in the health-care industry, and Sequenom, Inc. (NASDAQ:SQNM) is a significant player in the genetic-testing niche. But can the company expand its existing offerings to take maximum advantage of the opportunity? Let’s take an early look at what’s been happening with Sequenom, Inc. (NASDAQ:SQNM) over the past quarter and what we’re likely to see in its quarterly report on Thursday.
Stats on Sequenom, Inc. (NASDAQ:SQNM)
|Analyst EPS Estimate||($0.23)|
|Revenue Estimate||$32 million|
|Change From Year-Ago Revenue||107%|
|Earnings Beats in Past 4 Quarters||0|
Will Sequenom, Inc. (NASDAQ:SQNM) pass the test this quarter?
Analysts have gotten slightly more optimistic about Sequenom, Inc. (NASDAQ:SQNM)’s prospects in recent months, narrowing its loss estimate for the quarter by a penny per share and pushing losses $0.06 per share closer to breakeven for full-year 2013. But the shares haven’t reflected any of that optimism, with a loss of about 9% since early December.